HK1255083A1 - 用於治療肺動脈高壓的方法和組合物 - Google Patents

用於治療肺動脈高壓的方法和組合物

Info

Publication number
HK1255083A1
HK1255083A1 HK18114213.2A HK18114213A HK1255083A1 HK 1255083 A1 HK1255083 A1 HK 1255083A1 HK 18114213 A HK18114213 A HK 18114213A HK 1255083 A1 HK1255083 A1 HK 1255083A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
pulmonary hypertension
treating pulmonary
treating
Prior art date
Application number
HK18114213.2A
Other languages
English (en)
Inventor
Neil P Desai
Patrick Soon-Shiong
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of HK1255083A1 publication Critical patent/HK1255083A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK18114213.2A 2007-05-03 2018-11-07 用於治療肺動脈高壓的方法和組合物 HK1255083A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92772907P 2007-05-03 2007-05-03

Publications (1)

Publication Number Publication Date
HK1255083A1 true HK1255083A1 (zh) 2019-08-02

Family

ID=39637592

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114213.2A HK1255083A1 (zh) 2007-05-03 2018-11-07 用於治療肺動脈高壓的方法和組合物

Country Status (5)

Country Link
US (4) US20100166869A1 (zh)
EP (2) EP3326630A3 (zh)
CA (1) CA2686736A1 (zh)
HK (1) HK1255083A1 (zh)
WO (1) WO2008137148A2 (zh)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
TR200502189T1 (tr) 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP3248600B8 (en) 2005-02-18 2020-06-24 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
ES2691646T3 (es) 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
EP2944382A1 (en) 2006-04-26 2015-11-18 Micell Technologies, Inc. Coatings containing multiple drugs
CA2667228C (en) 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
LT2117520T (lt) 2006-12-14 2018-12-10 Abraxis Bioscience, Llc Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
EP3417859A1 (en) * 2007-03-07 2018-12-26 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
CA2688314C (en) 2007-05-25 2013-12-03 Micell Technologies, Inc. Polymer films for medical device coating
PT2155188E (pt) 2007-06-01 2013-12-19 Abraxis Bioscience Llc Métodos e composições para o tratamento de cancro recorrente
WO2009051780A1 (en) * 2007-10-19 2009-04-23 Micell Technologies, Inc. Drug coated stents
WO2009126401A1 (en) * 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
EP2271294B1 (en) 2008-04-17 2018-03-28 Micell Technologies, Inc. Stents having bioabsorbable layers
AU2009270849B2 (en) 2008-07-17 2013-11-21 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
EP2367425B1 (en) 2008-12-11 2018-02-28 Abraxis BioScience, LLC Combination therapy including a taxane and a further therapeutic agent
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
CN102427728A (zh) 2009-03-13 2012-04-25 阿布拉科斯生物科学有限公司 用硫代秋水仙碱衍生物进行联合治疗
FR2943539B1 (fr) * 2009-03-31 2011-07-22 Ethypharm Sa Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
WO2010120552A2 (en) 2009-04-01 2010-10-21 Micell Technologies, Inc. Coated stents
CN104997774A (zh) 2009-04-10 2015-10-28 齐海燕 新的抗衰老试剂及其鉴别方法
KR20120044279A (ko) 2009-04-15 2012-05-07 아브락시스 바이오사이언스, 엘엘씨 무-프리온 나노입자 조성물 및 방법
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
CA2772301A1 (en) 2009-08-25 2011-03-03 Abraxis Bioscience, Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
PT2552438T (pt) 2010-03-26 2016-07-07 Abraxis Bioscience Llc Métodos de tratamento de carcinoma hepatocelular
WO2011123393A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
JP5926724B2 (ja) 2010-03-29 2016-05-25 アブラクシス バイオサイエンス， エルエルシー がんを処置する方法
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
SG186109A1 (en) 2010-06-02 2013-01-30 Abraxis Bioscience Llc Methods of treating bladder cancer
US9399071B2 (en) 2010-06-04 2016-07-26 Abraxis Bioscience, Llc Methods of treatment of pancreatic cancer
CN105832703A (zh) 2010-06-07 2016-08-10 阿布拉科斯生物科学有限公司 治疗增殖性疾病的联合治疗方法
US20130210733A1 (en) * 2010-06-17 2013-08-15 Cytokinetics, Inc. Methods of treating lung disease
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
US20120237550A1 (en) * 2011-03-16 2012-09-20 Siemens Healthcare Diagnostics Inc. Maintaining Antibody-Binding Activity Of Immunosuppressant Drug Conjugates
AU2012249371B2 (en) 2011-04-28 2017-06-08 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
ME03532B (me) 2011-12-14 2020-04-20 Abraxis Bioscience Llc Upotreba polimernih ekscipijenata za liofilizaciju ili zamrzavanje parтikula
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
SI2919780T1 (sl) * 2012-11-14 2018-12-31 Bial - Portela & Ca., S.A. Derivati 1,3-dihidroimidazol-2-tiona za uporabo v zdravljenju pljučne arterijske hipertenzije in poškodbe pljuč
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
CA2900668A1 (en) 2013-02-11 2014-08-14 Abraxis Bioscience, Llc Treatment of melanoma with nanoparticles comprising paclitaxel
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
NZ630392A (en) 2013-03-12 2016-10-28 Abraxis Bioscience Llc Methods of treating lung cancer
CN105209035A (zh) 2013-03-13 2015-12-30 阿布拉科斯生物科学有限公司 治疗儿童实体瘤的方法
WO2014151853A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
JP2016519965A (ja) 2013-05-15 2016-07-11 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
EP3054948B1 (en) * 2013-10-08 2020-08-12 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CN106573067A (zh) * 2014-02-11 2017-04-19 拉姆医疗公司 用于淋巴管平滑肌瘤病治疗的雷帕霉素
FI3125875T3 (fi) * 2014-04-04 2023-08-24 Ai Therapeutics Inc Inhaloitava rapamysiiniformulaatio ikäsidonnaisten tilojen hoitoon
MX2017004440A (es) * 2014-10-07 2017-11-01 Lam Therapeutics Inc Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
JP6921759B2 (ja) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド 捕集装置および使用法
ES2897991T3 (es) 2015-06-29 2022-03-03 Abraxis Bioscience Llc Nanopartículas que comprenden sirolimus y una albúmina para uso en tratamiento de tumores de células epitelioides
RU2737934C2 (ru) 2016-04-04 2020-12-07 Крититек, Инк. Способы лечения солидных опухолей
EA201990820A1 (ru) * 2016-09-28 2019-10-31 Способы лечения митохондриальных и метаболических нарушений
AU2018205253B2 (en) 2017-01-06 2022-01-13 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) * 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
EP3453385A1 (de) 2017-09-07 2019-03-13 Justus-Liebig-Universität Gießen Erfindung betreffend nanopartikel enthaltend taxane zur inhalativen applikation
RU2020110399A (ru) 2017-10-03 2021-11-09 Крититек, Инк. Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
EP3768268A4 (en) 2018-03-20 2022-02-23 Abraxis BioScience, LLC METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE
CN112423737A (zh) * 2018-05-22 2021-02-26 阿布拉科斯生物科学有限公司 用于治疗肺高压的方法和组合物
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
AU2020241730A1 (en) * 2019-03-19 2021-10-28 Abraxis Bioscience, Llc Subcutaneous administration of nanoparticles comprising an mTOR inhibitor and albumin for treatment of diseases
KR20220075306A (ko) * 2019-07-15 2022-06-08 예일 유니버시티 폐동맥 고혈압을 치료하기 위한 방법 및 조성물
JP2022553426A (ja) 2019-10-28 2022-12-22 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物
TW202200135A (zh) * 2020-05-08 2022-01-01 國立大學法人熊本大學 一種新穎血管疾病治療劑
US20230414590A1 (en) * 2020-11-12 2023-12-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Therapeutic small molecules for treatment of pulmonary hypertension
WO2024025991A1 (en) * 2022-07-27 2024-02-01 The Methodist Hospital System Methods for diagnosis and treatment of pulmonary hypertension
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5997904A (en) * 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US20070116761A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6528067B1 (en) * 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
CN1245156C (zh) * 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US8137684B2 (en) * 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
BRPI9810945B8 (pt) 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
TR200502189T1 (tr) * 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
AU2003293529A1 (en) * 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20050038498A1 (en) * 2003-04-17 2005-02-17 Nanosys, Inc. Medical device applications of nanostructured surfaces
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
MXPA06013294A (es) * 2004-05-17 2007-02-02 Novartis Ag Combinacion de compuestos organicos.
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP3248600B8 (en) * 2005-02-18 2020-06-24 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CN105879114A (zh) 2005-02-18 2016-08-24 阿布拉西斯生物科学公司 用于整合入医疗装置的疏水性改善的药物
EP1868576A2 (en) * 2005-03-17 2007-12-26 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US7514549B2 (en) * 2005-04-16 2009-04-07 Michigan State University Tumor inhibition by modulating sprouty expression or activity
KR20080007607A (ko) * 2005-05-16 2008-01-22 노파르티스 아게 심혈관 질환의 치료 및/또는 예방을 위한 라파마이신유도체의 용도
ES2719093T3 (es) * 2005-08-31 2019-07-08 Abraxis Bioscience Llc Composiciones de fármacos poco solubles en agua con mayor estabilidad y métodos para su preparación
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
LT2117520T (lt) * 2006-12-14 2018-12-10 Abraxis Bioscience, Llc Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną
US7855024B2 (en) * 2006-12-27 2010-12-21 Proton Energy Systems, Inc. Compartmentalized storage tank for electrochemical cell system
EP3417859A1 (en) * 2007-03-07 2018-12-26 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
PT2155188E (pt) * 2007-06-01 2013-12-19 Abraxis Bioscience Llc Métodos e composições para o tratamento de cancro recorrente
WO2009126401A1 (en) * 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
EP2367425B1 (en) * 2008-12-11 2018-02-28 Abraxis BioScience, LLC Combination therapy including a taxane and a further therapeutic agent
KR20120044279A (ko) * 2009-04-15 2012-05-07 아브락시스 바이오사이언스, 엘엘씨 무-프리온 나노입자 조성물 및 방법
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
WO2011123393A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
US8183104B2 (en) * 2010-07-07 2012-05-22 Hobbs Christopher C Method for dual-channel nanowire FET device

Also Published As

Publication number Publication date
EP2146707A2 (en) 2010-01-27
US20210315823A1 (en) 2021-10-14
CA2686736A1 (en) 2008-11-13
US20100166869A1 (en) 2010-07-01
WO2008137148A2 (en) 2008-11-13
WO2008137148A3 (en) 2009-02-19
EP3326630A2 (en) 2018-05-30
US20180133157A1 (en) 2018-05-17
US20140271871A1 (en) 2014-09-18
EP3326630A3 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
HK1255083A1 (zh) 用於治療肺動脈高壓的方法和組合物
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
HK1200485A1 (zh) 促進再生的方法、組合物及設備
HK1218393A1 (zh) 用於治療肺高壓的複合物
PL2137210T3 (pl) Nowy sposób i kompozycje
ZA201001300B (en) Antigen-asjuvant compositions and methods
PT2894165T (pt) Métodos e composições para o tratamento de distúrbios associados ao complemento
EP2214707A4 (en) COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
EP2124985A4 (en) METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
PT2497505T (pt) Composições e métodos para a formação de armações
EP2120561A4 (en) COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE
IL210097A0 (en) Compositions and methods for treating unfluenza
EP2309858A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
GB0721291D0 (en) Methods and compositions
IL205248A0 (en) Compositions and methods for making androstenediones
EP2120994A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPOGLYKEMIC CONDITIONS
GB0719526D0 (en) Compositions and methods
EP2224911A4 (en) METHOD AND COMPOSITION FOR TREATING LUNG HAEMORRHAGIA
EP2142669A4 (en) SIRTUINE-BASED METHODS AND COMPOSITIONS FOR TREATING B-CATENIN RELATED DISORDERS
WO2011130605A9 (en) Compositions and methods for treating pulmonary hypertension
EP2170314A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PHENYLCETONURIA
EP2200627A4 (en) METHOD AND COMPOSITIONS FOR TREATING MELANOMA
GB0707188D0 (en) Novel method and compositions